On September 10, SNS Insider reported that the oral GLP‑1 therapeutics market is projected to soar from USD 6.81 billion in 2025 to USD 137.36 billion by 2035, a staggering 35% compound annual growth rate. Overall, this assessment signals a potential shift in how diabetes and obesity are treated, moving away from injections toward pills that deliver the same metabolic punch.
The FDA’s approval of oral Wegovy for chronic weight management has been the spark. Patients and physicians alike prefer the convenience of a pill over injections, and pharmaceutical companies are racing to meet that demand. Novo Nordisk’s semaglutide formulations dominate today, but non‑peptide candidates like orforglipron are already in late‑stage trials, promising even broader access and fewer restrictions tied to meal timing.
Regional Dynamics
North America leads the charge, expected to reach USD 70.50 billion by 2035, thanks to strong FDA regulation and consumer demand. Europe follows with USD 19.72 billion, driven by Germany’s infrastructure and the UK’s innovation in peptide scaffolds. Asia‑Pacific, however, is the fastest‑growing region, with a projected 42% CAGR, fueled by China’s expanding domestic pipeline and Japan’s expertise in peptide macrocycles.
Beyond Diabetes
While type 2 diabetes remains the largest indication, the fastest growth is in obesity and weight management. Oral GLP‑1s are opening treatment to a much wider patient pool, especially as telehealth and online pharmacies expand access. Analysts note that this combination of convenience, digital distribution, and non‑peptide innovation could make oral GLP‑1s one of the most transformative drug classes of the next decade.
The Bigger Picture
Challenges remain — high costs and limited production capacity could slow adoption. But the trajectory is clear: oral GLP‑1s are reshaping the metabolic therapy landscape, offering a pain‑free alternative that could reach hundreds of millions worldwide. For the peptide industry, this is a watershed moment, as oral formulations prove that peptide‑based therapies can break free from the needle and scale globally.
Related Coverage: The legal battle over retatrutide’s classification could redefine peptide regulation and compounding access. See our coverage of Eli Lilly v. RFK Jr..